Clinical Trial Update: Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed safety and efficacy of rituximab combined with interleukin-2 in high-risk non-Hodgkin lymphoma; the study has completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Rituximab (rituximab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: High Risk Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-10-06